A universal reporter cell line for bioactivity evaluation of engineered cytokine products (Q89866097)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

title

A universal reporter cell line for bioactivity evaluation of engineered cytokine products (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

author name string

Christian Pellegrino

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Dario Neri

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

publication date

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

page(s)

3234

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

9 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Emerging strategies for combination checkpoint modulators in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Immunocytokines for cancer treatment: past, present and future

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Chemokines and cancer: new immune checkpoints for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Application potential of toll-like receptors in cancer immunotherapy: Systematic review

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Measurement of cytokines by bioassays: theory and application

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

A convenient and reliable IL-2 bioassay using frozen CTLL-2 to improve the detection of helper T lymphocyte precursors

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Tumor Necrosis Factor (TNF) α quantification by ELISA and bioassay: effects of TNFα-soluble TNF receptor (p55) complex dissociation during assay incubations

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Crosstalk via the NF-kappaB signaling system

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

DNA-binding affinity and transcriptional activity of the RelA homodimer of nuclear factor kappa B are not correlated

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

The two NF-kappaB activation pathways and their role in innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Interleukin signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

IL-4-induced upregulation of adenine nucleotide translocase 3 and its role in Th cell survival from apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

IL-12 Acts Directly on DC to Promote Nuclear Localization of NF-κB and Primes DC for IL-12 Production

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Tumor Necrosis Factor Receptor Superfamily in T Cell Priming and Effector Function

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

The TNF Receptor Superfamily-NF-κB Axis Is Critical to Maintain Effector Regulatory T Cells in Lymphoid and Non-lymphoid Tissues

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Nf-kappa B, chemokine gene transcription and tumour growth

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Rationale for anti-CD137 cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

1 reference

7 January 2021

Immunology. Licence to kill.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Engineered antibody fragments and the rise of single domains

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Advances in antibody engineering for rheumatic diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and Metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Selective targeted delivery of TNFalpha to tumor blood vessels.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Human native soluble CD40L is a biologically active trimer, processed inside microsomes

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Structural basis for ligand-mediated mouse GITR activation

1 reference

https://api.crossref.org/works/10.1038%2FS41598-020-60182-4

7 January 2021

Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells

1 reference

12 December 2020

Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor

1 reference

12 December 2020

IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12.

1 reference

12 December 2020

[Nf-kB transcription factor: role in the pathogenesis of inflammatory, autoimmune, and neoplastic diseases and therapy implications]

1 reference

12 December 2020

10.1038/S41598-020-60182-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094407%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference